NO20033549L - Terapeutiske bindingsmolekyler - Google Patents

Terapeutiske bindingsmolekyler

Info

Publication number
NO20033549L
NO20033549L NO20033549A NO20033549A NO20033549L NO 20033549 L NO20033549 L NO 20033549L NO 20033549 A NO20033549 A NO 20033549A NO 20033549 A NO20033549 A NO 20033549A NO 20033549 L NO20033549 L NO 20033549L
Authority
NO
Norway
Prior art keywords
therapeutic
bonding molecules
molecules
bonding
therapeutic bonding
Prior art date
Application number
NO20033549A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033549D0 (no
Inventor
Gregorio Aversa
Frank Kolbinger
Jose M Carballido Herrera
Andras Aszodi
Jose W Saldanha
Bruce M Hall
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20033549D0 publication Critical patent/NO20033549D0/no
Publication of NO20033549L publication Critical patent/NO20033549L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033549A 2001-02-12 2003-08-11 Terapeutiske bindingsmolekyler NO20033549L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103389.3A GB0103389D0 (en) 2001-02-12 2001-02-12 Organic compounds
PCT/EP2002/001420 WO2002072832A2 (en) 2001-02-12 2002-02-11 Therapeutic binding molecules

Publications (2)

Publication Number Publication Date
NO20033549D0 NO20033549D0 (no) 2003-08-11
NO20033549L true NO20033549L (no) 2003-10-10

Family

ID=9908539

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033549A NO20033549L (no) 2001-02-12 2003-08-11 Terapeutiske bindingsmolekyler

Country Status (26)

Country Link
US (1) US20040096901A1 (de)
EP (1) EP1421191B1 (de)
JP (2) JP2004533816A (de)
KR (1) KR100752029B1 (de)
CN (1) CN100529074C (de)
AR (1) AR035539A1 (de)
AT (1) ATE526409T1 (de)
BR (1) BR0207151A (de)
CA (1) CA2437963A1 (de)
CZ (1) CZ20032129A3 (de)
EC (1) ECSP034714A (de)
ES (1) ES2374554T3 (de)
GB (1) GB0103389D0 (de)
HK (1) HK1071769A1 (de)
HU (1) HUP0401560A3 (de)
IL (1) IL157136A0 (de)
MX (1) MXPA03007197A (de)
NO (1) NO20033549L (de)
NZ (1) NZ548865A (de)
PE (1) PE20020871A1 (de)
PL (1) PL369516A1 (de)
RU (2) RU2405790C2 (de)
SK (1) SK10082003A3 (de)
TW (1) TWI332524B (de)
WO (1) WO2002072832A2 (de)
ZA (1) ZA200305911B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
MY143963A (en) * 2003-09-18 2011-07-29 Novartis Ag Therapeutic binding molecules
WO2006081620A1 (en) 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
AU2008258646A1 (en) * 2007-06-05 2008-12-11 Fondazione Centro San Raffaele Del Monte Tabor Induction of tolerogenic phenotype in mature dendritic cells
JP2013507919A (ja) * 2009-10-16 2013-03-07 ダウ アグロサイエンシィズ エルエルシー 植物細胞に生体分子を送達するためのデンドリマーナノテクノロジーの使用
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2502631A1 (de) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunsuppressor und seine Verwendung
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3026060A1 (de) 2014-11-26 2016-06-01 Miltenyi Biotec GmbH CD45R0-spezifischer, humanisierter Antikörper oder Fragment davon
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
UA41929C2 (uk) * 1994-03-17 2001-10-15 Мерк Патент Гмбх Анти-ефрр одноланцюжковий fv,молекула днк,яка його кодує, анти-ефрр антитіло,спосіб одержання анти-ефрр одноланцюжкового fv,спосіб одержання повного анти-ефрр антитіла та фармацевтична композиція (варіанти)
JPH09191886A (ja) * 1996-01-19 1997-07-29 Asahi Breweries Ltd ヒト高親和性ＩｇＥ受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体

Also Published As

Publication number Publication date
RU2405790C2 (ru) 2010-12-10
PL369516A1 (en) 2005-04-18
RU2003126168A (ru) 2005-03-10
BR0207151A (pt) 2004-10-05
AR035539A1 (es) 2004-06-02
HUP0401560A3 (en) 2012-09-28
GB0103389D0 (en) 2001-03-28
CN1551919A (zh) 2004-12-01
CA2437963A1 (en) 2002-09-19
RU2008100239A (ru) 2009-07-20
KR20040036684A (ko) 2004-04-30
EP1421191B1 (de) 2011-09-28
WO2002072832A2 (en) 2002-09-19
NZ548865A (en) 2008-03-28
HUP0401560A2 (hu) 2004-11-29
KR100752029B1 (ko) 2007-08-28
RU2328506C2 (ru) 2008-07-10
EP1421191A2 (de) 2004-05-26
WO2002072832A3 (en) 2004-03-25
NO20033549D0 (no) 2003-08-11
JP2004533816A (ja) 2004-11-11
SK10082003A3 (sk) 2004-03-02
ECSP034714A (es) 2003-09-24
MXPA03007197A (es) 2003-12-04
JP2009034108A (ja) 2009-02-19
CN100529074C (zh) 2009-08-19
ES2374554T3 (es) 2012-02-17
PE20020871A1 (es) 2002-11-11
ZA200305911B (en) 2004-06-28
ATE526409T1 (de) 2011-10-15
IL157136A0 (en) 2004-02-08
CZ20032129A3 (cs) 2003-11-12
US20040096901A1 (en) 2004-05-20
HK1071769A1 (en) 2005-07-29
TWI332524B (en) 2010-11-01

Similar Documents

Publication Publication Date Title
NO20033549L (no) Terapeutiske bindingsmolekyler
DK3210637T3 (da) Infusionssæt
DK1383560T4 (da) Infusionssæt
IS7236A (is) Meðferðarfræðileg ísókínólínefnasambönd
EE200300416A (et) Ravimvorm
DE50208638D1 (de) Katheter
NO20033205L (no) Terapeutiske kromanforbindelser
NO20035315D0 (no) Farmasöytiske kombinasjoner
DE60208982D1 (de) Fussbad
DE50209245D1 (de) Neuroprotektives medikament
DK1440083T3 (da) Molekyler
NO20014597D0 (no) Fremgangsmåte
IS2523B (is) Turn vindorkuvers
DE60214270D1 (de) Pumpeinheit
DE60220505D1 (de) Haarwaschmittel
DE60114244D1 (de) Osteosynthesevorrichtung
DE60211574D1 (de) Seriendruckgerät
ATA8202001A (de) Medikamentenapplikator
ATA5002002A (de) Vibrator
DE60229395D1 (de) Altung
DE10157913B4 (de) Therapietisch
DOP2001000232A (es) Combinación terapeutica
DE60206034D1 (de) Spritze
DE60204435D1 (de) Spritze
SE0103855D0 (sv) Therapeutic agents